protocol for the earco registry: a pan-european observational study in patients with α1-antitrypsin deficiency
Clicks: 148
ID: 165881
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
148 views
26 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #22 of 36 articles by views in journal of bioscience and bioengineering
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Rationale and objectives
Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that leads to an increased risk of emphysema and liver disease. Despite extensive investigation, there remain unanswered questions concerning the natural history, pathophysiology, genetics and the prognosis of the lung disease in association with AATD. The European Alpha-1 Clinical Research Collaboration (EARCO) is designed to bring together researchers from European countries and to create a standardised database for the follow-up of patients with AATD.
Study design and population
The EARCO Registry is a non-interventional, multicentre, pan-European, longitudinal observational cohort study enrolling patients with AATD. Data will be collected prospectively without interference/modification of patient's management by the study team. The major inclusion criterion is diagnosed severe AATD, defined by an AAT serum level <11 µM (50 mg·dL−1) and/or a proteinase inhibitor genotype ZZ, SZ or compound heterozygotes or homozygotes of other rare deficient variants. Assessments at baseline and during the yearly follow-up visits include lung function testing (spirometry, body plethysmography and diffusing capacity of the lung), exercise capacity, blood tests and questionnaires (symptoms, quality of life and physical activity). To ensure correct data collection, there will be designated investigator staff to document the data in the case report form. All data will be reviewed by the EARCO database manager.
Summary
The EARCO Registry aims to understand the natural history and prognosis of AATD better with the goal to create and validate prognostic tools to support medical decision-making.
| Reference Key |
greulich2020erjprotocol
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Timm Greulich;Alan Altraja;Miriam Barrecheguren;Robert Bals;Jan Chlumsky;Joanna Chorostowska-Wynimko;Christian Clarenbach;Luciano Corda;Angelo Guido Corsico;Ilaria Ferrarotti;Cristina Esquinas;Caroline Gouder;Ana Hećimović;Aleksandra Ilic;Yavor Ivanov;Sabina Janciauskiene;Wim Janssens;Malcolm Kohler;Alvils Krams;Beatriz Lara;Ravi Mahadeva;Gerry McElvaney;Jean-François Mornex;Karen O'Hara;David Parr;Eava Piitulainen;Karin Schmid-Scherzer;Niels Seersholm;Robert A. Stockley;Jan Stolk;Maria Sucena;Hanan Tanash;Alice Turner;Ruxandra Ulmeanu;Marion Wilkens;Arzu Yorgancioğlu;Ana Zaharie;Marc Miravitlles |
| Journal | journal of bioscience and bioengineering |
| Year | 2020 |
| DOI |
10.1183/23120541.00181-2019
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.